Stock Events

Tscan Therapeutics 

$5.51
19
+$0.23+4.36% Friday 20:00

Statistics

Day High
5.55
Day Low
5.26
52W High
9.69
52W Low
2.86
Volume
287,440
Avg. Volume
227,493
Mkt Cap
298.24M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

6
NOV
Earnings
 

Earnings

6NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.03
-0.69
-0.34
0
Expected EPS
-0.315
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TCRX. It's not an investment recommendation.
Alphabet
75408
GOOGL
Apple
65674
AAPL
Microsoft
61161
MSFT
Amazon
56625
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Adaptimmune Therapeutics
ADAP
Mkt Cap324.8M
Adaptimmune Therapeutics focuses on T-cell receptor (TCR) engineered T-cell therapies for cancer, similar to Tscan's approach.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space for oncology, overlapping with Tscan's focus.
Bluebird bio
BLUE
Mkt Cap108.22M
bluebird bio offers gene and cell therapies that target cancer, including CAR-T and TCR therapies, competing in the same space as Tscan.
Novartis
NVS
Mkt Cap244.75B
Novartis, with its approved CAR-T cell therapy Kymriah, competes in the oncology treatment space, similar to Tscan's focus.
Allogene Therapeutics
ALLO
Mkt Cap549.96M
Allogene Therapeutics focuses on allogeneic CAR-T therapies for cancer, competing in the broader cell therapy market against Tscan.
Precigen
PGEN
Mkt Cap316.49M
Precigen operates in the gene and cell therapy sector focusing on oncology, which includes competing technologies to Tscan's TCR therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is engaged in gene editing and cell therapy, including CAR-T projects, competing in the innovative therapy space for cancer.

Analyst Ratings

12$Average Price Target
The highest estimate is $15.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
Employees
175
Country
US
ISIN
US89854M1018

Listings

XNAS
US
TCRX